Forlong Biotechnology

Executive Summary

Forlong Biotechnology is a clinical-stage Chinese biotech developing next-generation cytokine therapeutics using its proprietary Fbody® long-acting technology and Syntokine® synthetic cytokine platform. The company's pipeline targets advanced solid tumors and non-muscle invasive bladder cancer (NMIBC), addressing significant unmet needs in oncology. Forlong's Syntokine platform enables the design of synthetic cytokines with enhanced pharmacokinetics and reduced toxicity, while Fbody extends half-life to improve dosing convenience. The company has advanced into Phase 2 clinical trials, indicating promising early clinical data. With a focus on immune-oncology, Forlong's approach aims to overcome limitations of natural cytokines such as short half-life and systemic toxicity. The company is privately held and based in Suzhou, China, benefiting from the region's robust biotech ecosystem. Given its innovative platforms and Phase 2 status, Forlong represents a compelling opportunity in the cytokine therapy space, though clinical validation and regulatory milestones remain key risks.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for lead candidate in advanced solid tumors60% success
• Q2 2027Phase 2 interim results in NMIBC55% success
• Q3 2026Potential partnership or licensing deal for Syntokine platform40% success